exwannabe,
Complex endpoints but thought out ahead of time because the variables were well understood. With DCVax the issues were complex, not well understood and needed new measures and buyin from all regulators at the end of the trial. Amarin has a fish oil pill not a much more complexly made treatment like L which had a need to develop manufacturing for mass production of a personalized treatment. Not even close to the same issues. The demand on the DCVax platform will be huge and not just for GBM. Try fitting that demand into a bottle. Manufacturing, manufacturing, manufacturing. You can set your NWBO clock to it. Best wishes.
Market Data 
Markets 
AI
